Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

Blood tests show potential for CRC detection, but follow-up falls short

About half patients completed a follow-up colonoscopy within six months of taking a blood-based colorectal cancer screening test, according to a study by investigators at UCLA Health Jonsson Comprehensive Cancer Center.

August 01, 2025

Vol.51 No.30

In Brief

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

A new partnership between the University of Arkansas for Medical Sciences Winthrop P. Rockefeller Cancer Institute and ARcare aims to improve colorectal cancer screening rates in seven rural Arkansas counties where late-stage diagnoses and cancer disparities are on the rise.

July 25, 2025

Vol.51 No.29

Clinical Roundup

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Tumor-infiltrating clonal hematopoiesis is prevalent across solid tumors with the highest incidence in non-small cell lung cancer and results in a higher rate of mortality, according to a study by Caris Life Sciences that independently validates recent findings on TI-CH.

July 25, 2025

Vol.51 No.29

Imaging’s ride to the bottom in clinical trials—and why it matters now

In cancer care, imaging has become a marvel of modern medicine. Advances in scanner technology, reconstruction algorithms, contrast agents, and diagnostic protocols have radically improved our ability to detect, track, and understand disease. Clinically, imaging is fast, accurate, and central to decision-making.

ACR to launch artificial intelligence economics committee

The American College of Radiology is launching a new Artificial Intelligence Economics Committee to help consolidate available resources and develop financial strategies to address development and deployment of radiologic AI tools.

July 18, 2025

Vol.51 No.28

Drugs & Targets

Braftovi combination receives approval in China for BRAFV600E-mutant metastatic colorectal cancer

Chinese authorities granted the marketing authorization for Braftovi (encorafenib) in combination with cetuximab, for the treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer, after prior systemic therapy.

July 18, 2025

Vol.51 No.28

Personalis, Tempus AI expand commercial partnership focused on ultra-sensitive cancer recurrence testing

YOU MAY BE INTERESTED IN

Blood tests show potential for CRC detection, but follow-up falls short

UAMS Winthrop P. Rockefeller Cancer Institute, ARcare partner to boost CRC screenings in rural Arkansas

Tumor-infiltrating clonal hematopoiesis findings validated by AI analysis

Imaging’s ride to the bottom in clinical trials—and why it matters now

ACR to launch artificial intelligence economics committee

Braftovi combination receives approval in China for BRAFV600E-mutant metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login